Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis

• Päätekijät: Jeayeon Park (Tekijä), Yun Bin Lee (Tekijä), Yunmi Ko (Tekijä), Youngsu Park (Tekijä), Hyunjae Shin (Tekijä), Moon Haeng Hur (Tekijä), Min Kyung Park (Tekijä), Dae-Won Lee (Tekijä), Eun Ju Cho (Tekijä), Kyung-Hun Lee (Tekijä), Jeong-Hoon Lee (Tekijä), Su Jong Yu (Tekijä), Tae-Yong Kim (Tekijä), Yoon Jun Kim (Tekijä), Tae-You Kim (Tekijä), Jung-Hwan Yoon (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Korean Liver Cancer Association, 2024-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background/Aim Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC). However, comparative efficacy studies are still limited. This study aimed to investigate the effectiveness of these treatments i...